Efficacy of novel CAR T cells targeting other antigens, such as CD22, CD30 and CD79b [176,177,178,179,180,181] and innate immunity-mediated CAR NK cells [182] on MYC overexpressing lymphomas are under investigation. This evidence concerns the gene MYC and lymphoma.